Response to Letter to ‘Serum <scp>CRP</scp> in Durvalumab‐Tremelimumab‐Treated <scp>HCC</scp> : Expanding the Inflammatory Narrative’AuthorsTakeshi Hatanaka (ORCID: https://orcid.org/0000-0003-3656-285X)Takashi Kumada (ORCID: https://orcid.org/0000-0003-2211-495X)Yutaka Yata (ORCID: https://orcid.org/0000-0002-4592-3509)Satoru Kakizaki (ORCID: https://orcid.org/0000-0003-0224-7093)InstitutionsNational Hospital Organization Takasaki Medical Center (JP)Hanwa Memorial Hospital (JP)Gunma Saiseikai Maebashi Hospital (JP)Osaka Metropolitan University (JP)Gifu Kyoritsu University (JP)Tokyo Metropolitan University (JP)Publication DetailsJournalLiver InternationalPublished2025-10-16DOIhttps://doi.org/10.1111/liv.70381Primary TopicLiver Disease Diagnosis and TreatmentTypearticleField-Weighted Citation Impact0.00Explore the Global Research Space Interactive Map